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Using X-ray and NMR data relating to the conformation of the antihypertensive, angiotensin-converting 
enzyme inhibitor, captopril, and structure-activity relationships of analogues, it has been possible to 
postulate with the aid of computer graphics, the orientation of the three functions, the thiol, the terminal 
carboxyl and the carbonyl group which are involved in binding to the enzyme. Bicyclic mimetics of 
captopril, with related arrays of these functions, have been designed and synthesized. Compounds with the 
closest approximation to the array in captopril are the most active inhibitors of angiotensin converting 
enzyme, in vitro. 
Angiotensin-converting enzyme Inhibitors Design Antihypertensive 
1. INTRODUCTION 
There is considerable interest in investigating 
the potential of the angiotensin-renin system for 
controlling blood pressure in man. Certain inhibi- 
tors of angiotensin-converting enzyme (ACE, EC 
3.4.15.1) which transforms the decapeptide angio- 
tensin I to the powerful vasoconstrictor octapep- 
tide angiotensin II offer promise as therapeutic 
agents. Useful antihypertensive properties have 
been demonstrated, clinically, for the nonapeptide 
SQ 20 881 and the orally-active inhibitors cap- 
topril (SQ 14 225, I) [I] and MK 421 (enalapril II) 
[2]. The two latter compounds are very active in- 
hibitors of ACE in vitro (table 2). 
tulated zinc atom in the enzyme while retaining a 
close similarity to the dipeptide Ala-Pro. The 
compound MK 421, which includes an Ala-Pro 
fragment in the molecule was the outcome of ex- 
tensive structure-activity studies; it is visualised as 
a transition stage analogue inhibitor [2]. 
Me 
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The molecular structure of ACE and, con- 
sequently, the details of its active site are un- 
known. Extensive evidence of structure-activity 
relationships of captopril and its close relatives is 
available. Using precise bond lengths and angles 
from the X-ray diffraction data for the captopril 
molecule [3] it becomes possible to postulate the 
favoured spatial orientation of functional groups 
that are important for binding. We have studied 
this to provide a basis for design of inhibitors with 
alternative molecular structures that might then be 
expected to show different characteristics in vivo. 
(I) 
2. EXPERIMENTAL 
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The thiol group in captopril was introduced by 
the Squibb investigators to co-ordinate with a pos- 
Computer graphics studies were carried out 
using a Megatek 7000 display processor interfaced 
to a PDPl l/40 computer and a Midas plotter. 
NMR spectra were determined on Varian XL-100 
and Bruker WM-300 spectrometers. X-ray diffrac- 
tion data were obtained by courtesy of Dr J.J. Daly 
(F. Hoffmann-La Roche, Basle). Full description 
of the chemistry will follow in a later paper. 
Enzyme was prepared according to [14]. Ac- 
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tivities were determined by monitoring the release 
of hippuric acid from the substrate hippuryl-his- 
tidyl-leucine (Hip-His-Leu) as in [ 151. The assay 
medium contained Hip-His-Leu (2 mM), NaCl 
(300 mM), in phosphate buffer (100 mM), at a 
final pH of 8.3, incubated with ACE for 30 min at 
37°C. 
3. RESULTS AND DISCUSSION 
There is good evidence from the earlier studies 
on captopril and related compounds that the pro- 
line carboxyl, the carbonyl and thiol groups are 
essential [4-61 whereas the methyl function [7] and 
the spacing of the essential groups influence the 
potency of inhibition. 
The co-ordinates of the 3 main binding sites 
may be deduced by analogy with known examples 
of substrate or inhibitor binding. In the case of the 
carboxyl group, it is assumed that it interacts with 
a positively charged centre in the enzyme (-NH3+ 
or -NH-C ,NH, @NH3+), lying in the vicinity of the 
loop represented ;o scale in fig. 1. There is good 
evidence of hydrogen bonding to the carbonyl 
Fig.1. The hoop generated for the carboxyl group of 
captopril by rotation about the C-CO;? bond. The 
positively charged group in the receptor binding site will 
lie some 2.8 A from a point on the circumference and 
the spherical sectors within which the H-bonding group 
of the receptor must lie for angles 8 of 150”, 160” and 
170”: 8 
C = 8 . . . . . H-N 
group [5]; this is postulated as favouring a tram 
orientation and interacting with an NH-group of 
the receptor: 
8 ,HN: 
n’ 
:c=o 
with an optimum angle 0 of 150-180°C. The hy- 
drogen bond donator of the enzyme is anticipated 
to lie within the sector of a sphere of radius 
- 1.8 A from the oxygen atom [8]. 
To postulate the volume of space within which 
the zinc-sulphur interaction may occur it has been 
assumed, in the first instance, that for the array: 
8 
Zn ““S_j-CH,>CH(Me)*C- 
00 0 
there should be free rotation about bonds @ and 
@ but for bond 0 the rotamer (a), which min- 
imises the interaction .of the inhibitor with the 
bulky enzyme-bound zinc atom, is very much 
more likely than the gauche forms (b) and (c): 
‘\& 
Ha. H& &H 
.Z,n. . . . Z:n L Zn. 
t& (b) (cl 
On this basis, and allowing free rotation about 
bonds 0 and @ , a rim-shaped mesh plot is 
produced for all possible positions of the zinc 
atom, as shown in fig.2; this indicates the surface 
of interaction with the thiol ligand. 
For the rotation about bonds @ and @ we 
deduced initially the locus of the sulphur atom, 
assuming no restriction in rotation. Using con- 
ventional molecular mechanics calculations (modi- 
fied Lennard-Jones [9-l l]), excluding all high 
energy rotational forms, a mesh plot (fig.3) was 
obtained for the locus with total energy < 50 kcal/ 
mol. When this data is combined with the earlier 
deductions involving the zinc atom in a tram posi- 
tion the mesh plot (fig.4) is obtained for the postu- 
lated conformation of captopril bound to the 3 
subsites of the enzyme. 
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Fig.2. Allowing free rotation about the single bonds: 
0 0 
-CH,-CH(Me)-C=O 
and [runs orientation about the CH2-S bond (rotamer 
a), the zinc receptor atom will lie in the rim-shaped 
mesh as shown. (CH2-??-Zn assumed to be 124”). 
Interestingly, this mesh plot accomodates the 
conformation for captopril in the solid state (X-ray 
diffraction data [3]) which is also the major 
rotamer in solution (l H-NMR studies [121). 
We have used fig.4 as a basis for designing new 
analogues of captopril which satisfy the criteria for 
binding to the active site. From earlier knowledge 
of the conformation of derivatives of piperazic 
acid [13] it was deduced that the critical subsites 
for binding in bicyclic compounds such as III 
would fall largely within the captopril mesh plot 
(Iig.4). The preparation of typical 5,6- and 6,6-bi- 
cyclic compounds is illustrated in table 1. A com- 
parison of ACE-inhibiting activities is in table 2. 
The conformations of key compounds III (as S- 
acetyl-methyl ester) and IX in the solid state have 
been determined by X-ray diffraction studies and 
in solution using high field lH-NMR studies. 
When these conformations were related to the en- 
ergy mesh plot for captopril there was a good cor- 
relation between the degree of fit and the observed 
activity for ACE inhibition. This is illustrated by 
the results for the pair of inhibitors VIII and IX. It 
appears from these results that for good binding to 
the enzyme the CH2SH and COOH groups should 
Fig.3. (a) The locus of the sulphur atoms allowing free 
rotation about bonds @ and 0; (b) The reduced 
locus excluding high energy rotational forms. 
Fig.4. The total composite picture of the proposed 
binding site for captopril. 
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Table 1 
The synthesis of representative examples of bicyclic ACE inhibitors 
October 1982 
/c CO,R + 
AcSCH2 COCI 
zY 
HN 
3 
CO2Me 
(a)(b)(c)(,d) 
R = CH3, CH,Ph III 
0 
Y N R/NKi + 
0 
R = W-$),Cl 
CO,Et 
/ 
CH,CH 
\ 3 
C02H 
(i)(j)(k) 
C 
0 
(e) (f)(g)(h) 
HS(CH2)“- N 
IV n=l 
V n=2 
VI n=3 
8 0 
CH3 (I)(m) (n) (0) 
Rl R2 
VII CH, SH CH3 
VIII CH3 CH,CH,SH 
IX CH,CH,SH CH, 
Reagents and conditions: (a) CH,Cl,, NaOH, 16 h, RT; (b) HBr/HOAc, 1.5 h, RT; (c) PCLJDMF, 2 h, 0°C; 
(d) MeOH, 1 M NaOH, 2 h, RT; (e) dioxan, - 1 h, RT; (I) MeOH/HCl, 16 h, RT; (g) AcSK, NaI, acetone, reflux, 18 h; 
(h) MeOH, NaOH, 2 h, RT; (i) CH,Cl,, 1 M NaOH, RT; (j) H,/Pd, MeOH; (k) HOAc, 2 h, 100°C; (1) NaOH, DMF, 
RT; (m) AcS(CH,),Br, 5 h, 75°C; (n) TFA, 1 h, RT; (0) NH,OH, 2 h, RT. 
Table 2 
Inhibition, in vitro of angiotensin-converting enzyme from rabbit lung 
Compound I II 111a IV v VI VII VIII IX 
150 (IIM)~ 0.007 0.004 0.038 0.7 0.48 6 1 43 0.1 
a Compounds III + IX racemic mixtures 
b See section 2 for details 
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be held tram to each other about the mean mo- 
lecular plane, e.g., III, in line with the proposed 
binding areas suggested in fig.4. The arrangement 
in space of the important molecular groups in the 
most active bicyclic compound III is not yet opti- 
mal but is better than for the compounds IV-IX. 
We are extending this study to other structures 
designed as ACE inhibitors. Evidently, this use of 
computerised molecular graphics could be applied 
to assist in other cases of drug design where there 
is a similar basis for utilising evidence of molecular 
conformation and biological activity measure- 
ments. 
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